CN109862895A - 结节性痒疹的治疗 - Google Patents

结节性痒疹的治疗 Download PDF

Info

Publication number
CN109862895A
CN109862895A CN201780065280.6A CN201780065280A CN109862895A CN 109862895 A CN109862895 A CN 109862895A CN 201780065280 A CN201780065280 A CN 201780065280A CN 109862895 A CN109862895 A CN 109862895A
Authority
CN
China
Prior art keywords
patient
nalbuphine
itching
treatment
method described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780065280.6A
Other languages
English (en)
Chinese (zh)
Inventor
T·希萨西亚
G·古德
A·霍伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trevi Therapeutics Inc
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of CN109862895A publication Critical patent/CN109862895A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780065280.6A 2016-10-25 2017-10-25 结节性痒疹的治疗 Pending CN109862895A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662412578P 2016-10-25 2016-10-25
US62/412,578 2016-10-25
PCT/US2017/058294 WO2018081273A1 (en) 2016-10-25 2017-10-25 Treatment of prurigo nodularis

Publications (1)

Publication Number Publication Date
CN109862895A true CN109862895A (zh) 2019-06-07

Family

ID=62025443

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780065280.6A Pending CN109862895A (zh) 2016-10-25 2017-10-25 结节性痒疹的治疗

Country Status (11)

Country Link
US (3) US20180125840A1 (https=)
EP (1) EP3532061A4 (https=)
JP (2) JP2019532112A (https=)
KR (1) KR102696347B1 (https=)
CN (1) CN109862895A (https=)
AU (1) AU2017350852A1 (https=)
BR (1) BR112019008241A2 (https=)
CA (1) CA3038544A1 (https=)
MX (1) MX2019004804A (https=)
NZ (1) NZ751972A (https=)
WO (1) WO2018081273A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019301134A1 (en) * 2018-07-11 2021-01-21 Trevi Therapeutics, Inc. Treatment of the pruritic symptoms of liver disease
JP2021531299A (ja) 2018-07-23 2021-11-18 トレビ セラピューティクス インコーポレイテッド 慢性咳嗽、息切れ、及び呼吸困難の治療
KR20220127849A (ko) * 2020-01-10 2022-09-20 트레비 테라퓨틱스, 인코포레이티드 날부핀의 투여 방법
US12508259B2 (en) 2022-02-01 2025-12-30 HUMANWELL PHARMACEUTICAL US, Inc. Pharmaceutical formulations containing Nalbuphine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104981246A (zh) * 2012-12-14 2015-10-14 特雷维治疗股份有限公司 治疗瘙痒的方法
WO2015192071A1 (en) * 2014-06-13 2015-12-17 Trevi Therapeutics, Inc. Methods for treating pruritus
CN105560202A (zh) * 2016-03-11 2016-05-11 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003261298A1 (en) * 2002-08-02 2004-02-23 Penwest Pharmaceuticals Company Sustained release formulations of metformin
JP2005162736A (ja) * 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物
US20050169991A1 (en) * 2003-12-12 2005-08-04 Penwest Pharmaceuticals Co. Sustained release torsemide dosage forms
HUE053838T2 (hu) * 2005-08-24 2021-07-28 Endo Pharmaceuticals Inc Nyújtott felszabadulású nabulfin-készítmények
EP2240110A4 (en) * 2008-01-29 2015-07-01 Superdimension Ltd TARGET IDENTIFICATION INSTRUMENT FOR LOCALIZATION IN THE BODY
US8987289B2 (en) * 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
WO2017120468A1 (en) * 2016-01-06 2017-07-13 Trevi Therapeutics, Inc. Therapeutic use of nalbuphine without aquaretic effects

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104981246A (zh) * 2012-12-14 2015-10-14 特雷维治疗股份有限公司 治疗瘙痒的方法
WO2015192071A1 (en) * 2014-06-13 2015-12-17 Trevi Therapeutics, Inc. Methods for treating pruritus
CN105560202A (zh) * 2016-03-11 2016-05-11 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAURA BROPHY: "Trevi Therapeutics Announces Positive Results from Phase 2 Trial in Prurigo Nodularis", 《HTTPS://WWW.BUSINESSWIRE.COM/NEWS/HOME/20161013005913/EN/》 *

Also Published As

Publication number Publication date
BR112019008241A2 (pt) 2019-07-16
KR102696347B1 (ko) 2024-08-19
EP3532061A4 (en) 2020-07-08
CA3038544A1 (en) 2018-05-03
MX2019004804A (es) 2019-08-22
US20230338367A1 (en) 2023-10-26
EP3532061A1 (en) 2019-09-04
NZ751972A (en) 2022-12-23
US20220347171A1 (en) 2022-11-03
JP2022191405A (ja) 2022-12-27
KR20190073385A (ko) 2019-06-26
WO2018081273A1 (en) 2018-05-03
AU2017350852A1 (en) 2019-04-11
US20180125840A1 (en) 2018-05-10
JP2019532112A (ja) 2019-11-07

Similar Documents

Publication Publication Date Title
EP3578173B1 (en) Dosage form containing oxycodone and naloxone
US12569453B2 (en) Use of tapinarof for the treatment of atopic dermatitis
JP2019131588A (ja) そう痒の処置法
US20230338367A1 (en) Treatment of prurigo nodularis
CN106535897A (zh) 用于治疗瘙痒的方法
CN109310656A (zh) 尿毒症性瘙痒症的治疗
BR122023024228A2 (pt) Usos de uma composição compreendendo nalbufina para o tratamento de falta de ar e dispneia
CN112672743A (zh) 肝病瘙痒症状的治疗
EP3352734A1 (en) Treatment of alopecia areata
CN109310691A (zh) 用于快速开始抗抑郁作用的给药方案
AU2015305430A1 (en) Method for treating hyperhidrosis
HK40003409A (en) Treatment of prurigo nodularis
HK40112834A (zh) 用於痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
HK40013011A (en) Methods for treating pruritus
HK1219669A1 (en) Dosage form containing oxycodone and naloxone
HK1111604B (en) Dosage form containing oxycodone and naloxone
HK1219669B (en) Dosage form containing oxycodone and naloxone
HK1150754A (en) Dosage form containing oxycodone and naloxone

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003409

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190607